196 related articles for article (PubMed ID: 20644484)
1. Manganese-based oral contrast agent for liver magnetic resonance imaging: evaluation of the time course and dose response of liver signal intensity enhancement.
Rief M; Huppertz A; Asbach P; Franiel T; Schwenke C; Hamm B; Taupitz M; Wagner M
Invest Radiol; 2010 Sep; 45(9):565-71. PubMed ID: 20644484
[TBL] [Abstract][Full Text] [Related]
2. Orally administered manganese with and without ascorbic acid as a liver-specific contrast agent and bowel marker for magnetic resonance imaging: phase I clinical trial assessing efficacy and safety.
Leander P; Golman K; Månsson S; Höglund P
Invest Radiol; 2010 Sep; 45(9):559-64. PubMed ID: 20644487
[TBL] [Abstract][Full Text] [Related]
3. Imaging liver metastases with a new oral manganese-based contrast agent.
Chabanova E; Logager V; Moller JM; Dekker H; Barentsz J; Thomsen HS
Acad Radiol; 2006 Jul; 13(7):827-32. PubMed ID: 16777556
[TBL] [Abstract][Full Text] [Related]
4. Mangafodipir trisodium (MnDPDP)-enhanced magnetic resonance imaging of the liver and pancreas.
Wang C
Acta Radiol Suppl; 1998; 415():1-31. PubMed ID: 9571956
[TBL] [Abstract][Full Text] [Related]
5. MRI of colorectal cancer liver metastases: comparison of orally administered manganese with intravenously administered gadobenate dimeglumine.
Brismar TB; Kartalis N; Kylander C; Albiin N
Eur Radiol; 2012 Mar; 22(3):633-41. PubMed ID: 21953376
[TBL] [Abstract][Full Text] [Related]
6. T2-weighted magnetic resonance imaging of the liver: evaluation of the effect in signal intensity after Gd-EOB-DTPA enhancement.
Tamada T; Ito K; Yoshida K; Sone T; Murakami K; Kanki A; Watanabe S; Higashi H; Yamashita T
J Comput Assist Tomogr; 2010; 34(2):182-6. PubMed ID: 20351500
[TBL] [Abstract][Full Text] [Related]
7. Orally administered manganese chloride: enhanced detection of hepatic tumors in rats.
Kreft BP; Baba Y; Tanimoto A; Finn JP; Stark DD
Radiology; 1993 Feb; 186(2):543-8. PubMed ID: 8421762
[TBL] [Abstract][Full Text] [Related]
8. Imaging of macrophages in soft-tissue infection in rats: relationship between ultrasmall superparamagnetic iron oxide dose and MR signal characteristics.
Lutz AM; Weishaupt D; Persohn E; Goepfert K; Froehlich J; Sasse B; Gottschalk J; Marincek B; Kaim AH
Radiology; 2005 Mar; 234(3):765-75. PubMed ID: 15665219
[TBL] [Abstract][Full Text] [Related]
9. Contribution of diffusion-weighted magnetic resonance imaging in the characterization of hepatocellular carcinomas and dysplastic nodules in cirrhotic liver.
Xu PJ; Yan FH; Wang JH; Shan Y; Ji Y; Chen CZ
J Comput Assist Tomogr; 2010 Jul; 34(4):506-12. PubMed ID: 20657216
[TBL] [Abstract][Full Text] [Related]
10. Comparison of manganese biodistribution and MR contrast enhancement in rats after intravenous injection of MnDPDP and MnCl2.
Ni Y; Petré C; Bosmans H; Miao Y; Grant D; Baert AL; Marchal G
Acta Radiol; 1997 Jul; 38(4 Pt 2):700-7. PubMed ID: 9245965
[TBL] [Abstract][Full Text] [Related]
11. Manganese-enhanced MRI (ME MRI) in evaluation of the auditory pathway in an experimental rat model.
Tang Z; Wu L; Xiao Z; Feng X; Sun X; Tang W; Wang J; Jin L
NMR Biomed; 2017 Feb; 30(2):. PubMed ID: 27976435
[TBL] [Abstract][Full Text] [Related]
12. A new manganese-based oral contrast agent (CMC-001) for liver MRI: pharmacological and pharmaceutical aspects.
Jørgensen JT; Rief M; Brismar TB; Wagner M; Albiin N
Acta Radiol; 2012 Sep; 53(7):707-13. PubMed ID: 22821959
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics and imaging properties of Gd-EOB-DTPA in patients with hepatic and renal impairment.
Gschwend S; Ebert W; Schultze-Mosgau M; Breuer J
Invest Radiol; 2011 Sep; 46(9):556-66. PubMed ID: 21623212
[TBL] [Abstract][Full Text] [Related]
14. Liposome encapsulated MnCl2 as a liver specific contrast agent for magnetic resonance imaging.
Niesman MR; Bacic GG; Wright SM; Swartz HJ; Magin RL
Invest Radiol; 1990 May; 25(5):545-51. PubMed ID: 2345086
[TBL] [Abstract][Full Text] [Related]
15. Oral manganese for liver imaging at three different field strengths.
Thomsen HS; Loegager V; Noergaard H; Chabanova E; Moller JM; Sonne J
Acad Radiol; 2004 Jun; 11(6):630-6. PubMed ID: 15172365
[TBL] [Abstract][Full Text] [Related]
16. Mangafodipir trisodium-enhanced MRI for the detection and characterization of focal hepatic lesions: is delayed imaging useful?
Chung JJ; Kim MJ; Kim KW
J Magn Reson Imaging; 2006 May; 23(5):706-11. PubMed ID: 16565954
[TBL] [Abstract][Full Text] [Related]
17. Dynamic contrast-enhanced MRI coupled with a subtraction technique is useful for treatment response evaluation of malignant melanoma hepatic metastasis.
Lee M; Baek SE; Moon J; Roh YH; Lim JS; Park MS; Kim MJ; Kim H
Oncotarget; 2016 Jun; 7(25):38513-38522. PubMed ID: 27229529
[TBL] [Abstract][Full Text] [Related]
18. Solitary pulmonary nodules: MR evaluation of enhancement patterns with contrast-enhanced dynamic snapshot gradient-echo imaging.
Gückel C; Schnabel K; Deimling M; Steinbrich W
Radiology; 1996 Sep; 200(3):681-6. PubMed ID: 8756914
[TBL] [Abstract][Full Text] [Related]
19. P03277-A New Approach to Achieve High-Contrast Enhancement: Initial Results of an Experimental Extracellular Gadolinium-Based Magnetic Resonance Contrast Agent.
Fries P; Müller A; Seidel R; Robert P; Denda G; Menger MD; Schneider G; Buecker A
Invest Radiol; 2015 Dec; 50(12):835-42. PubMed ID: 26186281
[TBL] [Abstract][Full Text] [Related]
20. Dynamic contrast enhanced MRI in the differential diagnosis of adrenal adenomas and malignant adrenal masses.
Inan N; Arslan A; Akansel G; Anik Y; Balci NC; Demirci A
Eur J Radiol; 2008 Jan; 65(1):154-62. PubMed ID: 17466481
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
